Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant (AF-219) in Asthma
NCT01993329Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of gefapixant in asthma (6 arms), sponsored by Merck & Co. Primary endpoint: Provocative Concentration (PC20) After Methacholine Challenge at Day 3. Started Dec 2013; status: completed.
02
Drugs
gefapixant
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01993329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01993329.